Program
pacritinib
Also written as “Pacritinib”, “SB1518” and “CYP450 Cocktail and Transporter Substrates with Pacritinib”.
Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Leukemia, Myelomonocytic, Chronic · COVID-19 · Hodgkin Disease, led by 4 companies.
Drug pagePacritinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Swedish Orphan Biovitrumits history only | 122 open or running | phase 3since Jan 18, 2013 | Jan 18, 2013 | Dec 30, 2026phase 2 · NCT06782373 |
| S*BIOits history only | 40 open or running | phase 2since Jul 20, 2008 | Jul 20, 2008 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Oct 21, 2015 | Oct 21, 2015 | none ahead |
| Theradex | 11 open or running | phase 2since Jun 5, 2025 | Jun 5, 2025 | Jul 2028phase 2 · NCT07033598 |
Also a collaborator on its studies: PSI CRO, PPD DEVELOPMENT, LP, Covance, SGS and QPS-Qualitix.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Theradex only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2025First study: phase 2 study in Leukemia, Myelomonocytic, ChronicFirst studyNCT07033598 · 66 planned · United States, United Kingdom
Ahead
- Jul 2028Primary completion: phase 2 study in Leukemia, Myelomonocytic, ChronicNCT07033598
TargetBeta
“The citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule
“Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor”ChEMBL 37, by rule
Studies
The one study Theradex leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07033598Leukemia, Myelomonocytic, Chronic · United States, United Kingdom | 2 | Recruiting | Jul 2028 | 66 |
How it is read
Names in the registry
- “Pacritinib”, 13 entries
- “SB1518”, 4 entries
- “CYP450 Cocktail and Transporter Substrates with Pacritinib”, 1 entry
- “Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib”, 1 entry
- “Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib”, 1 entry
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 8 studies
- Hematologic Neoplasms, 1 study
- Leukemia, Myelomonocytic, Chronic, 1 study
- COVID-19, 1 study
- Hodgkin Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.